Corrigendum to "The Discovery, Engineering and Characterisation of a Highly Potent Anti-Human IL-13 Fab Fragment Designed for Administration by Inhalation" [J. Mol. Biol. 425 (2013), 577-593]

J Mol Biol. 2013 Jun 12;425(11):2082. doi: 10.1016/j.jmb.2013.03.038. Epub 2013 Apr 5.

Authors

Daniel Lightwood¹, Victoria O'Dowd², Bruce Carrington², Vaclav Veverka³, Mark D Carr³, Markus Tservistas⁴, Alistair J Henry², Bryan Smith², Kerry Tyson², Sabrina Lamour², Marguerite Bracher², Kaushik Sarkar², Alison Turner², Alastair D Lawson², Tim Bourne², Neil Gozzard², Roger Palframan²

Affiliations

¹ UCB Pharma, 216 Bath Road, Slough, Berkshire SL1 3WE, UK. Electronic address: daniel.lightwood@ucb.com.
² UCB Pharma, 216 Bath Road, Slough, Berkshire SL1 3WE, UK.
³ Department of Biochemistry, University of Leicester, Leicester LE1 9HN, UK.
⁴ PARI Pharma GmbH, Munich, Germany.

PMID: 29890570
DOI: 10.1016/j.jmb.2013.03.038

No abstract available

Publication types

Published Erratum